Mark Baum, Harrow CEO

Har­row prices $60M of­fer­ing one day af­ter ac­quir­ing US, Cana­di­an rights to new dry eye treat­ment

Eye biotech Har­row Health is look­ing to raise $60 mil­lion af­ter buy­ing the rights to an eye prod­uct new­ly ap­proved by the FDA.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.